There is increasing evidence that gynecological disorders associated to chronic pelvic pain (CPP) and co-morbid diseases are characterized by a neuroimmune dysregulation, involving mainly mast cells' (MC) distribution/function and nerve terminal fibers. MCs dysregulation might also promote spinal and supraspinal alterations associated with CPP.
Collectively, these observations propose that a pharmacological strategy targeting MCs might represent an innovative strategy for the effective management of these disorders.
Collectively, these observations propose that a pharmacological strategy targeting MCs might represent an innovative strategy for the effective management of these disorders.
Available documents
KEYWORDS OF THIS ARTICLE
ON THE SAME TOPIC